Renalytix PLC (AIM:RENX) saw its shares surge by 38% following the US Food and Drug Administration (FDA) granting marketing authorisation for its KidneyIntelX.dkd prognostic test.
This artificial intelligence-enabled platform, the first of its kind, is a major development for the care management of adults with early-stage chronic (diabetic) kidney disease and type 2 diabetes.
The shares rose 29p to 104p.